#Canada #Vancouver #WAT Medical #HeadaTerm2 #Migraine Relief

A Significant Advancement in Migraine Relief: HeadaTerm2

In a recent announcement, WAT Medical Enterprise Ltd. celebrated the inclusion of its innovative migraine relief device, HeadaTerm 2, in the American Migraine Foundation's (AMF) Device Corner. This platform is dedicated to patient education and provides valuable recommendations on FDA-cleared devices that address migraine treatment through neuromodulation.

HeadaTerm 2 aims to offer a safe, non-invasive, and drug-free alternative for individuals suffering from migraine episodes. The device utilizes external trigeminal nerve stimulation (eTNS), delivering mild electrical impulses specifically to the trigeminal nerve region, which plays a pivotal role in the migraine pain pathway. By targeting this area, the device helps to moderate the transmission of pain signals associated with migraines, providing sufferers with a much-needed reprieve.

Clinical Evidence and FDA Clearance

Clinical support for HeadaTerm 2's efficacy comes from a randomized controlled trial published in The American Journal of Emergency Medicine, which revealed an impressive 69.66% decrease in migraine pain among participants who used the device. Notably, users reported a reduced need for rescue medications within two hours after using HeadaTerm 2, showcasing the potential of neuromodulation therapies in both acute care settings and for at-home management.

The device is FDA-cleared and eligible for reimbursement via Flexible Spending Accounts (FSA) and Health Savings Accounts (HSA), which makes it not only effective but also accessible for those seeking alternatives to traditional pharmaceutical treatments that often come with unwanted side effects.

Addressing a Global Crisis

As migraines impact over one billion individuals worldwide, the urgency for effective treatment solutions is paramount. WAT Medical is committed to leveraging clinical evidence and patient feedback to ensure technology is patient-centric and effective. By incorporating advanced research and development in wearable medical technology, WAT Medical aims to foster solutions that prioritize safety, portability, and validated outcomes.

Future Directions

The endorsement by the American Migraine Foundation epitomizes WAT Medical's dedication to pioneering accessible treatments for chronic conditions like migraines. The company's ongoing mission is to enhance access to drug-free therapies, thereby improving quality of life for those affected. The inclusion in the AMF Device Corner is not just a recognition but a call to action to continue refining and expanding the availability of such innovative solutions.

In conclusion, HeadaTerm 2 stands as a beacon of hope for many, signifying a shift towards evidence-based, non-pharmacological strategies in migraine management. As we look forward to next-generation devices and therapies, the landscape of treatment for migraines is gradually evolving into a more patient-friendly and scientifically-backed domain, fostering hope and relief for millions worldwide.

References:
1. American Migraine Foundation. (2024). Device Corner Neuromodulation Devices for Migraine. American Migraine Foundation
2. Hokenek, N. M., et al. (2021). Treatment of migraine attacks by transcutaneous electrical nerve stimulation in emergency department: A randomized controlled trial. The American Journal of Emergency Medicine, 39, 80–85.
3. www.watmedical.com
4. www.emeterm.com